Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Rituxan | Rituximab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
Rosiver | Ivermectin | Rosacea | List with criteria/condition | Complete | ||
Rozlytrek | Entrectinib | ROS1-positive NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
Rozlytrek | entrectinib | Extracranial solid tumours with NTRK gene fusion | Reimburse with clinical criteria and/or conditions | Complete | ||
Rukobia | fostemsavir | Human immunodeficiency virus type 1 (HIV-1) | Reimburse with clinical criteria and/or conditions | Complete | ||
Ruzurgi | amifampridine | Lambert-Eaton myasthenic syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
Ryaltris | olopatadine hydrochloride and mometasone | Seasonal allergic rhinitis | Pending | |||
Rybelsus | semaglutide | diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Rybrevant | amivantamab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Rybrevant | amivantamab | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Pending |